Lytgobi (futibatinib) — United Healthcare

Initial criteria

• Diagnosis of cholangiocarcinoma (intrahepatic or extrahepatic)
• Disease is one of the following: unresectable OR resected gross residual (R2) OR metastatic
• Positive for fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements
• Used as second line or subsequent treatment

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Lytgobi therapy

Approval duration

12 months